Development of a high-affinity ligand that binds irreversibly to Mel1b melatonin receptors.
Witt-Enderby
P A
PA
Department of Pharmacology and Toxicology, School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania 15282, USA. wittp@duq3.cc.duq.edu
Chu
G H
GH
Gillen
M L
ML
Li
P K
PK
D000345:Affinity Labels / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D000477:Alkylating Agents / Q000138:chemical synthesis* / Q000378:metabolism; D000478:Alkylation; D000577:Amides / Q000138:chemical synthesis* / Q000378:metabolism; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D015195:Drug Design; D008024:Ligands; D015394:Molecular Structure; D009281:Naphthalenes / Q000138:chemical synthesis* / Q000378:metabolism; D011485:Protein Binding; D011956:Receptors, Cell Surface / Q000145:classification / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000145:classification / Q000378:metabolism*; D044094:Receptors, Melatonin
D000345:Affinity Labels; D000477:Alkylating Agents; D000577:Amides; D008024:Ligands; C110192:N-(2-(2-(bromoacetoxy)-7-methoxynaphtyl)ethyl)-propionamide; D009281:Naphthalenes; D011956:Receptors, Cell Surface; D018160:Receptors, Cytoplasmic and Nuclear; D044094:Receptors, Melatonin